Author: admin

  • Which Is More Likely to Be a Millionaire Maker?

    Which Is More Likely to Be a Millionaire Maker?

    • Over the past decade, Bitcoin has been the top-performing asset in the world.

    • Bitcoin has been growing exponentially over time and could hit a price of $1 million by 2030.

    • While Ethereum has largely followed the path of Bitcoin over the past decade, it hasn’t been able to deliver quite the same level of performance.

    • 10 stocks we like better than Bitcoin ›

    Over the past decade, investing in hypergrowth cryptocurrencies has become a proven way to attain millionaire status. According to the latest Crypto Wealth Report from Henley & Partners, there are an estimated 241,700 crypto millionaires in the world right now.

    Of these, 145,100 are Bitcoin (CRYPTO: BTC) millionaires. But is Bitcoin still the most likely way to grow your wealth over time? Or could Ethereum (CRYPTO: ETH) potentially offer a faster path to millionaire status? Let’s take a closer look.

    The key to Bitcoin’s enormous success has been its ability to compound its performance, year after year, with just a few missteps along the way. Since 2010, Bitcoin has only had three losing years: 2014, 2018, and 2022. In every other year, it has ripped higher at a head-spinning rate.

    More than any other cryptocurrency, Bitcoin demonstrates the power of compounding returns. In the period from 2017 to 2025, Bitcoin grew at a compound annual growth rate (CAGR) of 50%. That’s all the more impressive given that it collapsed in value in both 2018 and 2022. But the other years were so phenomenal that they more than made up for the bad years.

    In fact, it’s getting to the point where investors think Bitcoin can double in value every year. At the start of this year, for example, the conventional wisdom was that Bitcoin would double in value, from $100,000 to $200,000. That hasn’t been the case, of course, but Bitcoin did hit a new all-time high of $126,000 in October.

    Ethereum has been no slouch, either. During that same time period, Ethereum grew at a CAGR of 33%. Ethereum, too, tends to follow a four-year cycle, in which three good years are followed by one absolutely miserable year. After growing by 472% in 2020 and 395% in 2021, for example, Ethereum promptly gave it all back. In 2022, Ethereum lost 68% of its value.

    Another way to evaluate the millionaire-maker potential of any cryptocurrency is by taking into account future growth projections. In most cases, these are built by evaluating the potential use cases of a cryptocurrency, and then estimating how much market share it might gain within a certain niche, vertical, or industry.

    Continue Reading

  • Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

    Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

    Combining darolutamide (Nubeqa) with androgen deprivation therapy (ADT) showed improvements in efficacy vs placebo plus ADT among patients with metastatic hormone-sensitive prostate cancer (HSPC) who were 75 years or older, according to subgroup findings from the phase 3 ARASENS trial (NCT02799602) published in European Urology Oncology.1

    Among patients who were 75 years or older, the median overall survival (OS) was not reached (NR; 95% CI, 45.4-NR) in the darolutamide arm vs 42.0 months (95% CI, 33.8-48.9) in the placebo arm (HR, 0.61; 95% CI, 0.41-0.91). In each respective arm, the median time to metastatic castration-resistant prostate cancer (CRPC) was NR (95% CI, 36.0-NR) vs 19.4 months (95% CI, 14.0-24.8; HR, 0.42; 95% CI, 0.28-0.64), and the median time to initiation of subsequent antineoplastic treatment was NR (95% CI, NR-NR) vs 24.9 months (95% CI, 20.0-34.0; HR, 0.35; 95% CI, 0.22-0.54).

    In a population of patients who were younger than 75, data showed a median OS that was NR (95% CI, NR-NR) with the darolutamide regimen and NR (95% CI, 45.0-NR) with the placebo combination (HR, 0.70; 95% CI, 0.58-0.84). Additionally, the median time to CRPC was NR (95% CI, NR-NR) vs 17.3 months (95% CI, 16.4-19.5) in each arm (HR, 0.35; 95% CI, 0.30-0.43). Investigators also noted a median time to initiation of subsequent antineoplastic therapy of NR (95% CI, NR-NR) vs 25.3 months (95% CI, 22.4-29.5) with each regimen (HR, 0.40; 95% CI, 0.34-0.48).

    “In patients aged [75 or older] in the ARASENS trial, darolutamide demonstrated improved efficacy vs placebo and favorable safety, consistent with the findings in patients aged [younger than 75],” lead study author Joan Carles Galceran, MD, PhD, a medical oncologist in the Department of Oncology at Hospital Universitari Vall d’Hebron in Barcelona, Spain, wrote with coauthors in the publication.1 “Thus, darolutamide and ADT with docetaxel can be considered a standard of care for patients with [metastatic] HSPC regardless of age.”

    In the international phase 3 ARASENS trial, patients were randomly assigned to receive darolutamide at 600 mg orally twice daily or matched placebo plus ADT and docetaxel. As part of this subgroup analysis, investigators assessed outcomes in patients who were younger than 75 (n = 1086) or 75 years and older (n = 219).

    The trial’s primary end point was OS. Secondary end points included treatment-emergent adverse effects (TEAEs), time to CRPC, time to pain progression, time to initiation of subsequent antineoplastic therapy, and time to worsening of disease-related physical symptoms.2

    Patients 18 years and older with cytologically or histologically confirmed adenocarcinoma of the prostate and metastatic disease were eligible for enrollment on the trial. Additional eligibility criteria included having an ECOG performance status of 0 or 1 and adequate bone marrow, liver, and renal function.

    Investigators noted similar baseline disease and demographic features across the darolutamide and placebo arms in both age subgroups, although ongoing comorbidities were more frequent in patients who were 75 years or older. The most frequent prior and ongoing comorbidity types in patients who were younger than 75 or 75 and older, respectively, included vascular (55% vs 67%), musculoskeletal or connective tissue (42% vs 42%), and metabolism or nutrition (35% vs 43%).

    Among patients 75 years and older in the darolutamide and placebo arms, 99% and 99% from each group had any-grade TEAEs, the most common of which included neutropenia (43% vs 46%), fatigue (33% vs 36%), and peripheral edema (30% vs 35%). Grade 3/4 TEAEs occurred in 74% vs 70% of each arm, with the most common including neutropenia (40% vs 41%) and febrile neutropenia (14% vs 9.7%).

    Among those who were younger than 75, 99.6% in the darolutamide arm and 99.0% of the placebo arm had TEAEs of any grade; the most common types of toxicity in each arm included alopecia (43% vs 42%), neutropenia (38% vs 37%), and fatigue (33% vs 32%). Grade 3/4 TEAEs were reported in 65% and 62% of each arm, with the most common toxicities including neutropenia (33% vs 33%) and febrile neutropenia (6.6% vs 6.9%).

    References

    1. Carles J, Tombal B, Hussain M, et al. Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase 3 ARASENS trial. Eur Urol Oncol. 2025l4:S2588-9311(25)00255-X. doi:10.1016/j.euo.2025.10.001
    2. Darolutamide in addition to standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer (ARASENS). ClinicalTrials.gov. Updated April 16, 2024. Accessed November 20, 2025. https://tinyurl.com/3f5h3a7k

    Continue Reading

  • Evaluating Valuation After Strong Share Price Growth

    Evaluating Valuation After Strong Share Price Growth

    Westgold Resources (ASX:WGX) has shown solid share price growth over the past quarter, with shares climbing nearly 69% in that time. Investors are likely watching closely as the company continues to ride this positive momentum.

    See our latest analysis for Westgold Resources.

    Looking beyond the past quarter, Westgold Resources’ momentum stands out, with an 88.6% share price return year-to-date and a 92.1% total shareholder return over the last year. That kind of sustained outperformance hints that investors are starting to recognize its progress and growth potential, particularly after management’s recent positive updates.

    If this kind of strong momentum has you wondering what other opportunities are out there, now’s a great chance to broaden your scope and discover fast growing stocks with high insider ownership

    With shares up strongly and investor optimism running high, the key question now is whether Westgold’s current price truly reflects the company’s fundamentals or if there remains untapped value for those considering a buy.

    Westgold Resources’ most widely followed valuation narrative suggests the shares have room to run, as its fair value estimate sits well above the latest close. Market optimism is high, yet the reasoning behind this impressive valuation hinges on specific developments that analysts believe could be major game changers.

    Extensive mine and infrastructure upgrades, specifically at Bluebird-South Junction, Beta Hunt, and the Higginsville plant, are expected to materially lift volumes, grades, and operational efficiency over FY ’26. These factors support net margin expansion as higher-quality ore feeds, cost savings, and productivity gains take hold.

    Read the complete narrative.

    Think this is just another bullish take? The calculation behind this upside view leans on projected gains in margins and some aggressive profit forecasts for the next few years. Wondering how analysts arrive at a price nearly a fifth above today’s? Find out the forecasted numbers and the financial logic driving this bold valuation.

    Result: Fair Value of $6.83 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent low ore grades or failure to deliver expected cost reductions could quickly undermine these bullish forecasts and slow Westgold’s upward momentum.

    Find out about the key risks to this Westgold Resources narrative.

    While the fair value estimate sees upside, a look at the price-to-earnings ratio tells a starkly different story. Westgold trades at 148.2 times earnings, which is far above the Australian metals and mining industry’s 19.6x and its peers’ average of 27.5x. Even compared to the fair ratio of 36.2x, the current multiple stands out as steep. This raises the risk the shares might be priced for perfection. Are the expectations built into this premium justified, or could sentiment turn sharply if ambitions are not met?

    See what the numbers say about this price — find out in our valuation breakdown.

    ASX:WGX PE Ratio as at Nov 2025

    If you want to take a different perspective or have your own insights to test, it takes less than three minutes to shape your version of the narrative. Do it your way

    A great starting point for your Westgold Resources research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

    Seize your chance to uncover untapped opportunities beyond Westgold. Don’t give other investors the first move. Fresh ideas could put you ahead of the market.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include WGX.AX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Klarna Group’s Stock Slides 24% as New Payment Partnerships Spark Valuation Debate

    Klarna Group’s Stock Slides 24% as New Payment Partnerships Spark Valuation Debate

    • Wondering if Klarna Group might be undervalued, or if the recent market buzz is masking hidden risks? You are definitely not alone, and now is the perfect time to dig deeper.

    • In the last month, Klarna Group’s stock has dropped by 24.3%, and it is down a striking 36.6% year-to-date. This performance puts the company firmly on the radar of both contrarian investors and those watching for warning signs.

    • Recently, Klarna has been making headlines with announcements about expanding its payment solutions and forming new partnerships with major retailers. These developments are grabbing investor attention and adding to the stock’s volatility. They could indicate new growth opportunities, but they also raise questions about the sustainability of Klarna’s current strategy and how the market is reacting to these bold steps.

    • According to our valuation checklist, Klarna Group is undervalued in only 1 out of 6 checks right now. Next, we will break down what the numbers actually say and then show you a smarter way to really understand what “fair value” means for stocks like Klarna.

    Klarna Group scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Excess Returns valuation model examines how effectively Klarna Group generates returns above its cost of equity, essentially measuring how much real value is created for shareholders after accounting for the capital invested in the business. This model is especially relevant for financial firms, where return on invested capital and sustainable growth are key drivers of actual intrinsic value.

    Looking at Klarna Group’s latest data, the company has a Book Value of $6.32 per share and is projected to achieve a Stable Earnings Per Share (EPS) of $0.27, based on weighted future Return on Equity estimates from 8 different analysts. The estimated Cost of Equity stands at $0.64 per share. However, the calculated Excess Return is negative, at $-0.37 per share. Klarna’s average Return on Equity is a modest 3.37%, with a forecasted Stable Book Value of $8.09 per share, as estimated by 5 analysts.

    When applied, the Excess Returns model implies an intrinsic value that is significantly below Klarna’s current share price. The model indicates the stock is overvalued by 15,675.1%. This reflects that Klarna is struggling to generate returns high enough to justify its capital cost and market valuation.

    Result: OVERVALUED

    Our Excess Returns analysis suggests Klarna Group may be overvalued by 15675.1%. Discover 926 undervalued stocks or create your own screener to find better value opportunities.

    Continue Reading

  • Huntington’s Disease Research Over Six Decades: Global Insights, Gaps, and Future Directions

    Huntington’s Disease Research Over Six Decades: Global Insights, Gaps, and Future Directions

    Continue Reading

  • Whatsapp group chats might soon get custom tags for members

    Whatsapp group chats might soon get custom tags for members

    What’s happened? WhatsApp is testing a new way for people to identify themselves inside group chats. Spotted by WABetaInfo, the latest WhatsApp beta for Android introduces a new feature that lets users assign and display custom tags in…

    Continue Reading

  • Who dies in ‘Tulsa King’ Season 3 finale? Ending explained

    Who dies in ‘Tulsa King’ Season 3 finale? Ending explained

    Spoiler alert! We’re discussing the ending of the Season 3 “Tulsa King” finale. Stop reading if you haven’t seen it yet and don’t want to know.

    Robert Patrick, who plays “Tulsa King” baddie Jeremiah Dunmire, knew his odious crime family leader…

    Continue Reading

  • Heavy traffic expected for 4 days, Dh25 parking fees activated

    Heavy traffic expected for 4 days, Dh25 parking fees activated

    1. Take the Dubai Metro

    • Direct access: The Red Line stops at World Trade Centre Station, saving time and eliminating parking stress.

    • Nol card fares: Dh15 (Silver) or Dh25 (Gold) round-trip. Top-ups are simple via the nol Pay app or station…

    Continue Reading

  • Black Friday streaming deals include six months of Apple TV+ for only $36

    Black Friday streaming deals include six months of Apple TV+ for only $36

    Apple TV+ is offering six months of access for only $36 for Black Friday. The deal is live now for new and eligible returning subscribers and runs through December 1, giving you a chance to stream shows like Silo, The Morning Show and For All…

    Continue Reading

  • SpaceX launches 28 Starlink satellites on new Falcon 9 rocket from California

    SpaceX launches 28 Starlink satellites on new Falcon 9 rocket from California

    SpaceX introduced a new Falcon 9 rocket into its fleet on Sunday (Nov. 23), with he launch of 28 satellites for its Starlink megaconstellation in low Earth orbit.

    The launch, from Space Launch Complex 4 East (SLC-4E) at the Vandenberg Space Force…

    Continue Reading